- Home
- KW vs CVAC Comparison
KW vs CVAC Comparison
Compare KW & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KW
- CVAC
- Stock Information
- Founded
- KW 1977
- CVAC 2000
- Country
- KW United States
- CVAC Germany
- Employees
- KW N/A
- CVAC N/A
- Industry
- KW Real Estate
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- KW Finance
- CVAC Health Care
- Exchange
- KW Nasdaq
- CVAC Nasdaq
- Market Cap
- KW 1.0B
- CVAC 1.2B
- IPO Year
- KW 1992
- CVAC 2020
- Fundamental
- Price
- KW $7.56
- CVAC $5.34
- Analyst Decision
- KW
- CVAC Hold
- Analyst Count
- KW 0
- CVAC 3
- Target Price
- KW N/A
- CVAC $6.83
- AVG Volume (30 Days)
- KW 679.9K
- CVAC 450.0K
- Earning Date
- KW 11-05-2025
- CVAC 11-12-2025
- Dividend Yield
- KW 6.35%
- CVAC N/A
- EPS Growth
- KW N/A
- CVAC N/A
- EPS
- KW N/A
- CVAC 1.01
- Revenue
- KW $531,500,000.00
- CVAC $599,540,810.00
- Revenue This Year
- KW N/A
- CVAC N/A
- Revenue Next Year
- KW $2.36
- CVAC $23.40
- P/E Ratio
- KW N/A
- CVAC $5.31
- Revenue Growth
- KW 6.96
- CVAC 675.15
- 52 Week Low
- KW $5.98
- CVAC $2.37
- 52 Week High
- KW $11.88
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- KW 39.12
- CVAC 41.61
- Support Level
- KW $7.36
- CVAC $5.33
- Resistance Level
- KW $8.16
- CVAC $5.41
- Average True Range (ATR)
- KW 0.22
- CVAC 0.03
- MACD
- KW -0.01
- CVAC -0.00
- Stochastic Oscillator
- KW 25.00
- CVAC 12.50
About KW Kennedy-Wilson Holdings Inc.
Kennedy-Wilson Holdings Inc is a real estate investment company that owns, operates, and invests in real estate both on its own and through its investment management platform. The Company focuses on multifamily and office properties, as well as industrial and debt investments. It has two business segments; the Consolidated Portfolio includes investment activities that involve ownership of multifamily units, office, retail and industrial space, and one hotel, and The Co-Investment Portfolio segment consists of investments the Company makes with partners in which it receives fees, performance allocations that it earns on its fee-bearing capital and distributions and profits from its ownership interest in the underlying operations of its co-investments.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.